|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Residual renal function in peritoneal dialysis with failed allograft and minimum immunosuppression显示文摘Immunosuppression(IS) is often withdrawn in patients with end stage renal disease secondary to a failed renal allograft, and this can lead to an accelerated loss of residual renal function(RRF). As maintenance of RRF appears to provide a survival benefit to peritoneal dialysis(PD) patients, it is not clear whether this benefit of maintaining RRF in failed allograft patients returning to PD outweigh the risks of maintaining IS. A 49 year-old Caucasian male developed progressive allograft failure nine years after living-donor renal transplantation. Hemodialysis was initiated via tunneled dialysis catheter(TDC) and IS was gradually withdrawn. Two weeksafter IS withdrawal he developed a febrile illness, which necessitate removal of the TDC and conversion to PD. He was maintained on small dose of tacrolimus(1 mg/d) and prednisone(5 mg/d). Currently(1 year later) he is doing exceedingly well on cycler-assisted PD. Residual urine output ranges between 600-1200 m L/d. Total weekly Kt/V achieved 1.82. RRF remained well preserved in this patient with failed renal allograft with minimal immunosuppressive therapy. This strategy will need further study in well-defined cohorts of PD patients with failed allografts and residual RRF to determine efficacy and safety. | Nadear Elmahi éva Csongrádi Kenneth Kokko Jack R Lewin Jamie Davison Tibor Fülp | 2013 | World Journal of Transplantation2013，3，2： | 5 |
| 2 | Characteristics, covariances, andaverage returns: 1929-1997显示文摘 | Davis James L Eugene F Fama and Kenneth R | 2000 | Journal of Finance2000，55，： | 1 |
| 3 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial显示文摘 | George L Bakris Pantelis A Sarafidis Matthew R Weir Bj?rn Dahl?f Bertram Pitt Kenneth Jamerson Eric J Velazquez Linda Staikos-Byrne Roxzana Y Kelly Victor Shi Yann-Tong Chiang Michael A Weber | 2010 | The Lancet2010，，9721： | 1 |
| 4 | Consumer confidence and stock returns 显示文摘 | KENNETH L F MEIR S | 2003 | Journal of Portfolio2003，2003，1： | 1 |
| 5 | Cellular and ultrastructural changes in mesophyll and bundle sheath cells of Maize in response to water stress 显示文摘 | Kenneth L G Michael F B Daniel C | 1974 | Plant Physiology1974，54，： | 1 |
| 6 | Animal behavior: geomagnetic map used in sea-turtle navigation显示文摘 | Kenneth J L Catherine M Lohmann F | 2004 | Nature2004，428，： | 1 |
| 7 | Ligand design and metal-ion recognition interaction of nikel ( Ⅱ ) with 17- to 19-membered macrocycles containing O2N3 donor and O3N2 donor sets and X-ray structure of the parent 17-membered macrocyclic ligand显示文摘 | KENNETH R A ATHONY J L LEONARD F L | 1983 | J Amer Chem Soc1983，105，4： | 1 |
| 8 | Physical activity among adolescents in Taiwan 显示文摘 | CHEN L J M ANNE M H KENNETH R F | 2007 | Asia Pac J Clin Nutr2007，16，2： | 1 |
| 9 | Effects of water stress on the ultrastructure of leaf ceils of Sorghum bicolor 显示文摘 | Kenneth L G Daniel C Michael F B | 1976 | Plant Physiolo- gy1976，57，： | 1 |
| 10 | Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report显示文摘 | Victor J. Dzau Kenneth Bernstein David Celermajer Jerome Cohen Bj?rn Dahl?f John Deanfield Javier Diez Helmut Drexler Roberto Ferrari Wiek van Gilst Lennart Hansson Burkhard Hornig Ahsan Husain Colin Johnston Harold Lazar Eva Lonn Thomas Lüscher John Manc | 2002 | Cardiovascular Drugs and Therapy2002，，2： | 1 |
| 11 | A hierarchical approach for one-dimensional cutting stock problems in the steel industry that maximizes yield and minimizes overgrading 显示文摘 | Vasko F J Newhart D D Kenneth L | 1999 | European Journal of Operational Research1999，114，1： | 1 |
| 12 | A new classification of Cyperaceae (Poales) supported by phylogenomic data显示文摘Cyperaceae(sedges)are the third largest monocot family and are of considerable economic and ecological importance.Sedges represent an ideal model family to study evolutionary biology due to their species richness,global distribution,large discrepancies in lineage diversity,broad range of ecological preferences,and adaptations including multiple origins of C4 photosynthesis and holocentric chromosomes.Goetghebeur′s seminal work on Cyperaceae published in 1998 provided the most recent complete classification at tribal and generic level,based on a morphological study of Cyperaceae inflorescence,spikelet,flower,and embryo characters,plus anatomical and other information.Since then,several family-level molecular phylogenetic studies using Sanger sequence data have been published.Here,more than 20 years after the last comprehensive classification of the family,we present the first family-wide phylogenomic study of Cyperaceae based on targeted sequencing using the Angiosperms353 probe kit sampling 311 accessions.In addition,62 accessions available from GenBank were mined for overlapping reads and included in the phylogenomic analyses.Informed by this backbone phylogeny,a new classification for the family at the tribal,subtribal,and generic levels is proposed.The majority of previously recognized suprageneric groups are supported,and for the first time,we establish support for tribe Cryptangieae as a clade including the genus Koyamaea.We provide a taxonomic treatment including identification keys and diagnoses for the 2 subfamilies,24 tribes,and 10 subtribes,and basic information on the 95 genera.The classification includes five new subtribes in tribe Schoeneae:Anthelepidinae,Caustiinae,Gymnoschoeninae,Lepidospermatinae,and Oreobolinae. | Isabel Larridon Alexandre R.Zuntini Étienne Léveillé-Bourret Russell L.Barrett Julian R.Starr AMuthama Muasya Tamara Villaverde Kenneth Bauters Grace E.Brewer Jeremy J.Bruhl Suzana M.Costa Tammy L.Elliott Niroshini Epitawalage Marcial Escudero Isabel Fairlie Paul Goetghebeur Andrew LHipp Pedro Jiménez-Mejías Izai ABSabino Kikuchi Modesto Luceño JoséIgnacio Márquez-Corro Santiago Martín-Bravo Olivier Maurin Lisa Pokorny Eric HRoalson Ilias Semmouri David A.Simpson Daniel Spalink WWayt Thomas Karen L.Wilson Martin Xanthos Félix Forest William J.Baker | 2021 | Journal of Systematics and Evolution2021，59，4： | 1 |
| 13 | Relative value of natural cavities and nesting houses for wood ducks 显示文摘 | Bellrose F C Kenneth L Johnson K L | 1964 | Journal of Wildlife Management1964，28，4： | 1 |
| 14 | Intrusion and Misuse Detection in Large-Scale Systems显示文摘 | Robert F Erbacher Kenneth L Walker Deborah A Frincke | 2002 | lEEE computer Graphics and Applications2002，，： | 1 |
| 15 | Nutrient content of seagrass and epiphytes in the northern Gulf of Mexico:Evidence of phosphorus and nitrogen limitation显示文摘 | MATTHEW W J KENNETH L H J JAMES W F | 2006 | Aquatic Botany2006，85，： | 1 |
| 16 | Early invasive strategy in elderly patients with non-ST-elevation acute coronary syndromes显示文摘 | Francesco L Kenneth D Giovanni F | 2005 | Eur Heart J2005，7，： | 1 |
| 17 | Urgent endovasculal treatment of acute symptomatic occlusion of the cervical internal carotid artery显示文摘 | Huan Wang Giuseppe L Kenneth F | 2003 | J Neurosurg2003，99，： | 1 |
| 18 | Early invasive strategy in elderly patients with non ST elevation acute coronary syndromes 显示文摘 | Francesco L Kenneth D Giovanni F | 2005 | Eur Heart J2005，7，： | 1 |
| 19 | The relationship of psychological separation and parental attachment to the career maturity of college freshmen from intact families显示文摘 | Hee-Yeong L Kenneth F H | | 0，，04： | 1 |
| 20 | 雷米普利、替米沙坦或二者联用对心血管病高危人群肾脏结局的影响(ONTARGET研究):一项多中心、随机、双盲、对照试验显示文摘背景血管紧张素受体阻断剂(ARB)和血管紧张素转换酶抑制剂(ACEI)都可以减少蛋白尿,二者联用可能比单一用药更有效。目前还没有长期临床试验比较两者对肾功能的影响。本研究比较了雷米普利(一种ACEI)、替米沙坦(一种ARB)或二者联用对患有动脉粥样硬化性血管病或糖尿病合并终末器官损害的人群(年龄≥55岁)肾脏结局的影响。方法临床试验从2001年开始,到2007年结束。经过3周的导入期,25620例受试者被随机分配至10mg/d雷米普利组(n=8576)、80mg/d替米沙坦组(n=8542)或10mg/d雷米普利+80mg/d替米沙坦组(n=8502;中位随访期为56个月),同时检测肾功能和尿蛋白。主要肾脏结局为透析、血清肌酐加倍和死亡的复合终点。采用意向性治疗分析。本研究已在ClinicalTrials.gov注册,编号为NCT00153101。结果试验期间,784例患者因低血压症状提前终止随机治疗(联合用药组406例,雷米普利组149例,替米沙坦组229例)。替米沙坦组和雷米普利组发生复合终点事件的例数相近[替米沙坦组1147例(13.4%),雷米普利组1150例(13.5%);HR1.00(95%C10.92~1.09)],但在联合用药组有所增加[1233例(14.5%);HR1.09(95%CI1.01-1.18),P=0.037]。次要肾脏结局(透析或血清肌酐加倍)的发生例数在替米沙坦组(189例,2.21%)和雷米普利组(174例,2.03%)相近(HR1.09,95%C10.89~1.34),但在联合用药组显著增加(212例,2.49%:HR1.24,95%CI1.01~1.51.P=0.038)。肾小球滤过率估计值在雷米普利组下降最少,为-2.82ml/(min·1.73m^2)(s=17.2),而在替米沙坦组为-4.12ml/(min·1.73m^2)(S=17.4,P〈0.0001),在联合治疗组为-6.11ml/(min·1.73m^2)(S=17.9,P〈0.0001)。与雷米普利组相比,替米沙坦组(P=0.004)和联合用药组(P=0.001)较少发生尿蛋白排泄增加。结论在心血管病高危人群中,替米沙坦和雷米普利对肾脏结局的影响相同。尽管联合用药比单一治疗能更大程度减少蛋白尿,但总体上其增加了肾脏结局事件。基金 勃林格殷格翰公司。 | Johannes F E Mann, Roland E Schmieder Matthew McQueen Leanne Dyal Helmut Schumacher Janice Pogue Xingyu Wang Aldo Maggioni Andrzej Budaj Suphachai Chaithiraphan Kenneth Dickstein Matyas Keltai Kaj Metsarinne Ali Oto Alexander Parkhomenko Leopoldo S Piegas Tage L Svendsen Koon KTeo Salim Yusuf 刘欣(译) 王兴宇(审) | 2009 | 世界临床医学2009，，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员